The revolution comes to prenatal diagnosis
2020 * Incorporation of TrisoNIM NeoSeq to our range of fetal DNA tests in maternal blood, giving a qualitative leap in non-invasive prenatal genetic diagnosis with the inclusion of the dominant monogenic diseases.
Quality continues to be our focus
2020 * At NIMGenetics we achieved ENAC accreditation – ISO 15189 Standard for the area of fetal aneuploidy screening (chromosomes 13. 18. 21. X and Y), as well as for the determination of fetal sex in maternal blood by massive sequencing (NGS ), corresponding to TrisoNIM Basic and Basic Plus.
Committed to the early detection of gynecological cancer
2019-2020 * NIMGenetics reaches agreements for the distribution of GynEC-DX (2020) and GynTect (2019), which has allowed us to fully enter into the early detection and prevention of gynecological cancer.
NIMGenetics strengthens its presence in Mexico and Portugal
2019 * NIMGenetics strengthens its presence in Mexico and Portugal with the opening of its own office in both countries and the reinforcement of the commercial team.
ISO 9001:2015 certification
NIMGenetics achieves the certification of its management system by Bureau Veritas, in accordance with the requirements of ISO 9001:2015. The scope of this certification applies, for the moment, to the provision of genetic diagnostic analysis services in the preanalytical, analytical and post-analytical stages for the specialties of genomics, non-invasive prenatal testing and molecular diagnosis.
Innovative SME Accreditation
2018 * The Ministry of Economy and Competitiveness has renewed our recognition as an innovative company accredited by our activity in the field of Research, Development and Technological Innovation (R+D+i).
We open new offices in Alcobendas
2017 * Business complex Vega Norte (Alcobendas). Photo courtesy Villar Soba Inversiones.
1st Spanish company to obtain ISO 15189 Accreditation for KaryoNIM Postnatal 60K
2017 * NIMGenetics has the accreditation ISO15189 for the study of array-CGH since June 2015, being the first laboratory in Spain to demonstrate compliance with this standard, which accredits and demonstrates in an objective and independent manner the commitment of a laboratory with quality and with the technical competence (accreditation number ENAC 1212/LE2336).
Apposite Capital invests 7 million euros in NIMGenetics
2017 * ¡¡Apposite Capital bets on our big FAMILY investing 7 mill. €!! http://goo.gl/cn7eI8 😎💪💪💪🔬💰
Innovative SME recognition 2016
2016 * It’s coming!! This afternoon @FEIN recognizes us as an Innovative SME of 2016. How much you want the ceremony to start !! THANK YOU!!
We got ISO and we are Innovative SME of 2016
After many months of hard and intense work we became the first Spanish company, and one of the few European, to receive this accreditation for our array-CGH technology. On the other hand, we received several awards among which stands out as an Innovative SME of the year 2016 (granted by FEIN).
We go to Brazil and start our ISO for Array-CGH
2015 * NIMGenetics Brazil becomes a reality and we landed in person in one of the most important markets in the world. In addition, we started working with the objective of achieving the UNE-EN-ISO 15189: 2013 Accreditation for our array-CGH technology.
We are already in Brazil!
2014 * We are already in Brazil! #NIMGeneticsBrasil. Via @epocanegocios http://glo.bo/29NMZnJ @esamper
2014 * We invest significant resources to reach new markets such as Colombia, Chile, Peru, Paraguay, Uruguay and Portugal; since we understand that they can be the spearhead of our positioning and international development.
Prize for TrisoNIM and our Internationalization begins
2013 * TrisoNIM® is awarded within the Awards for the 100 best ideas of 2012, awarded by Actualidad Económica, in the health category. BGI invites us to the International Congress of Noninvasive Fetal Diagnosis in Prague and Agilent Technologies to its headquarters in California as expert advisors in technology of in situ Hybridization (FISH). We
The only non-invasive prenatal test performed entirely in Spain
2012 * TrisoNIM®Advance: ONLY NON-INVASIVE PRENATAL TEST CARRIED OUT IN SPAIN http://bit.ly/1ydJ4rv #líderes
TrisoNIM® arrives, the “Prenatal Revolution”
2012 * We revolutionized prenatal diagnosis by launching a Non-Invasive Prenatal Screening Test for pregnant women for the first time in Spain, which we call TrisoNIM® (in collaboration with the Beijing Genomics Institute, BGI). In turn, we continue to develop new services aimed at different neurological and oncological pathologies: KaryoNIM® Autism 180K, KaryoNIM® Stem Cells,
Redesign and launch of new Services with Quality Certificates
2011 * We developed KaryoNIM® Postnatal, launched a new KaryoNIM® Prenatal and obtained the Quality Certification of the Cytogenetics European Quality Association as a certified laboratory for genetic diagnosis by Array-CGH Methods. In addition, we obtain the 1st place in the Biotechnology category and 6th place in the General in the National Entrepreneur-Based Companies XXI
2010 * We received the award for “Best Growth Project in SMEs” (IE Business School) and we became the only company in southern Europe with the Certified Service Provider certification from Agilent Technologies. We received the INNPACTO-ASCIVAR Project in collaboration with the company TiGENIX (Grupo Genetrix) to design an array of genetic diagnosis focused on
2008 * NIMGenetics was born by the doctors Enrique Samper, Juan Cruz Cigudosa and Sara Álvarez as the main founding partners. In just one year, NIMGenetics is positioned as a pioneer and leader in Spain in genomic analysis by Array-CGH for genetic diagnosis; being endorsed by the CDTI (Center for Industrial Technological Development) for the